| BCBS Federal Medical & Drug | 2.04.41 Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.60 JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.61 Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.63 Use of Common Genetic Variants (Single Nucleotide Variants) to Predict Risk of Nonfamilial Breast Cancer | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.78 Molecular Markers in Fine Needle Aspiration of the Thyroid | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.85 BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.93 Genetic Cancer Susceptibility Panels Using Next Generation Sequencing | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.97 Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.107 Carrier Screening for Genetic Diseases | 2025-12-01 |